NeonMind Biosciences Named as a Top Industry Innovator in Inaugural Issue of Psychedelia Magazine
NeonMind Biosciences Named as a Top Industry Innovator inInaugural Issue of Psychedelia Magazine
Announces Participation in Microdose's Wonderland: Miami on November 8-9, 2021
Vancouver, B.C. – November 5, 2021: NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FRA:6UF) (“NeonMind''), an integrated drug development and wellness company, today announced thatNeonMind was ranked third in Psychedelia Magazine’s “8 Industry Innovators'' segment within themagazine’s inaugural Winter 2022 issue. NeonMind was recognized for its dual approach in bringingpsychedelic treatments to patients in need through its anticipated specialty mental health clinic launchand its drug development program for novel obesity treatments.
Separately, Rob Tessarolo, President & CEO of NeonMind, will participate in Microdose's Wonderland:Miami, the nation’s largest psychedelic medicine business event, which brings together an impressivegroup of global psychedelic medicine leaders, including scientists and researchers, as well as, investors,entrepreneurs, therapists, patients, and government officials, all championing the growth of the psychedelicmedicine industry. Mr. Tessarolo will be participating in one-on-one meetings during the event.
“We are honored to be ranked as a top industry innovator in Psychedelia Magazine, which is a testamentto our strategy of pursuing unique modalities across the psychedelic treatment spectrum,” said RobertTessarolo, President & CEO of NeonMind. “As we are advancing quickly across our drug developmentprogram and planned specialty clinics launch, we look forward to sharing our updates with industryparticipants at the Wonderland event in Miami.”
Wonderland: Miami will be held at the Adrienne Arsht Center for the Performing Arts in Miami, FL onNovember 8-9, 2021.
For more information regarding the event or to schedule a one-on-one meeting with management,please contact KCSA Strategic Communications at [email protected].
About NeonMind Biosciences Inc.NeonMind operates two divisions: (i) a pharmaceutical division engaged in drug development ofpsychedelic compounds with two lead psilocybin-based drug candidates targeting obesity; and (ii) amedical services division focused on launching specialty mental health clinics that integrate psychedelictherapeutics into traditional psychotherapy settings.
In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programstargeting obesity. NeonMind’s lead candidate, NEO-001, employs psilocybin as an agonist at theserotonin 5- HT2A receptor, which is involved in the hallucinogenic effect of psychedelics. The Company’ssecond drug candidate, NEO-002, employs low-dose psilocybin as an agonist at the 5-HT2C receptor,which controls appetite.
NeonMind established a medical services division with the goal of launching NeonMind-brandedspecialty mental health clinics in Canada that incorporate evidence-backed innovative treatments toaddress a variety of mental health needs. For more information on NeonMind, go towww.NeonMindBiosciences.com.
Rob Tessarolo, President & Chief Executive Officer, NeonMind Biosciences [email protected]: 416-750-3101
Investor Relations:KCSA Strategic CommunicationsScott Eckstein/Tim [email protected]: 212-896-1210
The Canadian Securities Exchange has not reviewed, approved nor disapproved the contents of this newsrelease.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements contained in this press release constitute forward-looking information. Thesestatements relate to future events or NeonMind’s future performance. The use of any of the words"could", "expect", "believe", "will", "projected", "estimated" and similar expressions and statementsrelating to matters that are not historical facts are intended to identify forward-looking information andare based on NeonMind’s current belief or assumptions as to the outcome and timing of such futureevents. Actual future results may differ materially. In particular, NeonMind’s drug development plans, itsability to retain key personnel, and its expectation as to the development of its intellectual property andother steps in its preclinical and clinical drug development constitute forward-looking information. Actualresults and developments may differ materially from those contemplated by forward-lookinginformation. Readers are cautioned not to place undue reliance on forward-looking information. Thestatements made in this press release are made as of the date hereof. NeonMind disclaims any intentionor obligation to publicly update or revise any forward-looking information, whether as a result of newinformation, future events or otherwise, except as may be expressly required by applicable securitieslaws.